Combination of vascular endothelial growth factor inhibitors and laser therapy for diabetic macular oedema: a review.

Related Articles

Combination of vascular endothelial growth factor inhibitors and laser therapy for diabetic macular oedema: a review.

Clin Exp Ophthalmol. 2016 May;44(4):335-9

Authors: Mehta H, Gillies MC, Fraser-Bell S

Abstract
This review provides a perspective on published and ongoing clinical trials of vascular endothelial growth factor inhibitors (anti-VEGF agents) combined with laser therapy for diabetic macular oedema (DMO). Although there was little short-term benefit in combining prompt macular laser with anti-VEGF therapy for centre-involving DMO in the Diabetic Retinopathy Clinical Research Network (DRCRnet) Protocol I study, deferred macular laser was still required in over 40% of study eyes in DRCRnet Protocol T. Macular laser was applied in more than 30% of eyes with centre-involving DMO receiving ranibizumab in the RISE and RIDE studies. For non centre-involving DMO the evidence-base still supports use of focal macular laser alone, although clinicians should be cautious about applying laser too close to the foveal avascular zone with the availability of pharmacotherapy. Ongoing clinical trials are assessing whether selectively targeting areas of peripheral retinal ischaemia with laser reduces the number of anti-VEGF injections to stabilise DMO and whether combining macular micropulse laser with anti-VEGF therapy is beneficial in DMO.

PMID: 27061760 [PubMed - indexed for MEDLINE]

http://ift.tt/2mcUhKn